I-Ming Cho

Associate Director at AltruBio

I-Ming Cho has held a variety of roles in the biotechnology and pharmaceutical industries. In 2011, they began as a Postdoctoral Fellow at Academia Sinica, where they studied the role of a novel protein, Puf-A, in germ cell development and embryonic stem cell differentiation in mammalians. In 2013, they became a Researcher at Medigen Biotechnology Corp., where they developed a novel human vaccine platform using virus-like particles. In 2014, they moved to Phalanx Biotech Group as a Senior Researcher, conducting market surveys, designing and quality controlling DNA microarrays. In 2015, they joined EirGenix. Inc. as a Senior Scientist, leading the group for microbial cell line engineering. In 2018, they became a Project Manager at AbGenomics B.V. Taiwan Branch. Currently, they are an Associate Director at AltruBio Inc., managing clinical trials to ensure projects are executed effectively.

I-Ming Cho obtained a Doctor of Philosophy (Ph.D.) in Molecular Genetics and Biochemistry from The Ohio State University between 2004 and 2010.

Links


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


AltruBio

AltruBio is a privately held biotechnology company headquartered in the San Francisco Bay Area that is focused on developing novel antibody therapeutics for the treatment of immunological diseases with high unmet medical needs.


Industries

Employees

11-50

Links